Journal of Diagnostics Concepts & Practice ›› 2025, Vol. 24 ›› Issue (02): 135-145.doi: 10.16150/j.1671-2870.2025.02.004
Previous Articles Next Articles
Received:
2024-10-26
Accepted:
2025-01-08
Online:
2025-04-25
Published:
2025-07-11
Contact:
LI Yan
E-mail:yanli2022@sjtu.edu.cn
CLC Number:
WU Qi, FAN Bonan, LI Yan. Analysis and interpretation of the 2022 Global Cancer Statistics Report: cancer burden and epidemiological trends in China and the world[J]. Journal of Diagnostics Concepts & Practice, 2025, 24(02): 135-145.
Table 1
Top ten cancer incidence and death statistics in the world,2022
排位 | 发病情况 | 死亡情况 | |||||
---|---|---|---|---|---|---|---|
发病部位 | 新发病例数(万) | 年龄标化发病率(/10万) | 发病部位 | 死亡例数(万) | 年龄标化发病率(/10万) | ||
男女合并 | 全部癌症 | 1 996.5 | 196.9 | 全部癌症 | 973.7 | 91.7 | |
1 | 肺癌 | 248.0 | 23.6 | 肺癌 | 181.7 | 16.8 | |
2 | 乳腺癌 | 230.9 | 46.8 | 结直肠癌 | 90.4 | 8.1 | |
3 | 结直肠癌 | 192.6 | 18.4 | 肝癌 | 75.8 | 7.4 | |
4 | 前列腺癌 | 146.7 | 29.5 | 乳腺癌 | 66.6 | 12.7 | |
5 | 胃癌 | 96.8 | 9.2 | 胃癌 | 66.0 | 6.1 | |
6 | 肝癌 | 86.5 | 8.6 | 胰腺癌 | 46.7 | 4.2 | |
7 | 甲状腺癌 | 82.1 | 9.1 | 食管癌 | 44.5 | 4.3 | |
8 | 宫颈癌 | 66.1 | 14.1 | 前列腺癌 | 39.7 | 7.3 | |
9 | 膀胱癌 | 61.4 | 5.6 | 宫颈癌 | 34.8 | 7.1 | |
10 | 非霍奇金淋巴瘤 | 55.3 | 5.6 | 白血病 | 30.5 | 3.1 | |
男性 | 全部癌症 | 1 030.6 | 212.5 | 全部癌症 | 542.7 | 109.7 | |
1 | 肺癌 | 157.2 | 32.1 | 肺癌 | 123.3 | 24.8 | |
2 | 前列腺癌 | 146.7 | 29.4 | 肝癌 | 52.1 | 10.9 | |
3 | 结直肠癌 | 104.5 | 21.9 | 结直肠癌 | 48.9 | 9.9 | |
4 | 胃癌 | 62.7 | 14.0 | 胃癌 | 42.7 | 8.6 | |
5 | 肝癌 | 60.0 | 12.8 | 前列腺癌 | 39.7 | 7.3 | |
6 | 膀胱癌 | 47.1 | 12.7 | 食管癌 | 31.8 | 6.5 | |
7 | 食管癌 | 36.5 | 9.3 | 胰腺癌 | 24.7 | 5.0 | |
8 | 非霍奇金淋巴瘤 | 31.1 | 7.6 | 白血病 | 17.3 | 3.7 | |
9 | 白血病 | 27.8 | 6.6 | 膀胱癌 | 16.6 | 3.1 | |
10 | 肾癌 | 27.8 | 6.2 | 非霍奇金淋巴瘤 | 14.4 | 2.9 | |
女性 | 全部癌症 | 965.8 | 186.2 | 全部癌症 | 431.0 | 76.8 | |
1 | 乳腺癌 | 229.6 | 48.6 | 乳腺癌 | 66.6 | 12.6 | |
2 | 肺癌 | 90.8 | 16.2 | 肺癌 | 58.4 | 9.8 | |
3 | 结直肠癌 | 82.7 | 15.2 | 结直肠癌 | 39.3 | 6.5 | |
4 | 宫颈癌 | 66.1 | 14.1 | 宫颈癌 | 34.8 | 7.1 | |
5 | 甲状腺癌 | 61.5 | 13.6 | 肝癌 | 23.7 | 4.1 | |
6 | 子宫癌 | 42.0 | 8.4 | 胃癌 | 23.2 | 3.9 | |
7 | 胃癌 | 34.1 | 6.0 | 胰腺癌 | 22.0 | 3.5 | |
8 | 卵巢癌 | 32.4 | 6.6 | 卵巢癌 | 20.7 | 4.0 | |
9 | 肝癌 | 26.5 | 4.8 | 白血病 | 13.2 | 2.5 | |
10 | 非霍奇金淋巴瘤 | 24.2 | 4.6 | 食管癌 | 12.7 | 2.2 |
Table 2
Top ten cancer incidence and death statistics in China,2022
排位 | 发病情况 | 死亡情况 | |||||
---|---|---|---|---|---|---|---|
发病部位 | 新发病例数(万) | 年龄标化发病率 (/10万) | 发病部位 | 死亡例数(万) | 年龄标化发病率 (/10万) | ||
男女合并 | 全部癌症 | 482.5 | 201.6 | 全部癌症 | 257.4 | 96.5 | |
1 | 肺癌 | 106.1 | 40.8 | 肺癌 | 73.3 | 26.7 | |
2 | 结直肠癌 | 51.7 | 20.1 | 肝癌 | 31.7 | 12.6 | |
3 | 甲状腺癌 | 46.6 | 24.6 | 胃癌 | 26.0 | 9.4 | |
4 | 肝癌 | 36.8 | 15.0 | 结直肠癌 | 24.0 | 8.6 | |
5 | 胃癌 | 35.9 | 13.7 | 食管癌 | 18.7 | 6.7 | |
6 | 乳腺癌 | 35.7 | 33.0 | 胰腺癌 | 10.6 | 3.9 | |
7 | 食管癌 | 22.4 | 8.3 | 乳腺癌 | 7.5 | 6.1 | |
8 | 宫颈癌 | 15.1 | 13.8 | 脑肿瘤 | 5.7 | 2.5 | |
9 | 前列腺癌 | 13.4 | 9.7 | 宫颈癌 | 5.6 | 4.5 | |
10 | 胰腺癌 | 11.9 | 4.4 | 白血病 | 5.0 | 2.4 | |
其他癌症 | 107.0 | 其他癌症 | 49.3 | ||||
男性 | 全部癌症 | 253.4 | 209.6 | 全部癌症 | 162.9 | 127.5 | |
1 | 肺癌 | 65.9 | 52.0 | 肺癌 | 51.6 | 39.5 | |
2 | 结直肠癌 | 30.8 | 24.7 | 肝癌 | 23.0 | 19.1 | |
3 | 肝癌 | 26.8 | 22.7 | 胃癌 | 18.2 | 13.8 | |
4 | 胃癌 | 24.7 | 19.5 | 结直肠癌 | 14.3 | 10.9 | |
5 | 食管癌 | 16.7 | 13.1 | 食管癌 | 14.0 | 10.7 | |
6 | 前列腺癌 | 13.4 | 9.7 | 胰腺癌 | 6.1 | 4.7 | |
7 | 甲状腺癌 | 12.5 | 13.3 | 前列腺癌 | 4.8 | 3.3 | |
8 | 膀胱癌 | 7.3 | 5.7 | 膀胱癌 | 3.3 | 2.3 | |
9 | 胰腺癌 | 6.7 | 3.3 | 脑肿瘤 | 3.2 | 2.9 | |
10 | 肾癌 | 4.7 | 4.1 | 白血病 | 2.9 | 2.8 | |
其他癌症 | 43.9 | 其他癌症 | 21.7 | ||||
女性 | 全部癌症 | 229.1 | 197.0 | 全部癌症 | 94.5 | 67.8 | |
1 | 肺癌 | 40.2 | 30.3 | 肺癌 | 21.7 | 14.7 | |
2 | 乳腺癌 | 35.7 | 33.0 | 结直肠癌 | 9.7 | 6.5 | |
3 | 甲状腺癌 | 34.1 | 36.5 | 肝癌 | 8.7 | 6.2 | |
4 | 结直肠癌 | 20.9 | 15.7 | 胃癌 | 7.9 | 5.3 | |
5 | 宫颈癌 | 15.1 | 13.8 | 乳腺癌 | 7.5 | 6.1 | |
6 | 胃癌 | 11.2 | 8.3 | 宫颈癌 | 5.6 | 4.5 | |
7 | 肝癌 | 10.0 | 7.4 | 食管癌 | 4.7 | 2.9 | |
8 | 子宫癌 | 7.8 | 6.8 | 胰腺癌 | 4.5 | 3.1 | |
9 | 卵巢癌 | 6.1 | 5.7 | 卵巢癌 | 3.3 | 2.6 | |
10 | 食管癌 | 5.7 | 3.8 | 脑肿瘤 | 2.5 | 2.2 | |
其他癌症 | 42.3 | 其他癌症 | 18.4 |
[1] |
BRAY F, LAVERSANNE M, WEIDERPASS E, SOERJOMATARAM I. The ever-increasing importance of cancer as a leading cause of premature death worldwide[J]. Cancer,2021,127(16):3029-3030.
doi: 10.1002/cncr.33587 pmid: 34086348 |
[2] | CHEN S, CAO Z, PRETTNER K, et al. Estimates and Projections of the Global Economic Cost of 29 Cancers in 204 Countries and Territories From 2020 to 2050[J]. JAMA Oncol,2023,9(4):465-472. |
[3] |
SOERJOMATARAM I, BRAY F. Planning for tomorrow: global cancer incidence and the role of prevention 2020-2070[J]. Nat Rev Clin Oncol,2021,18(10):663-672.
doi: 10.1038/s41571-021-00514-z pmid: 34079102 |
[4] |
GBD 2019 Cancer Risk Factors Collaborators. The global burden of cancer attributable to risk factors, 2010-19: a systematic analysis for the Global Burden of Disease Study 2019[J]. Lancet,2022,400(10352):563-591.
doi: 10.1016/S0140-6736(22)01438-6 pmid: 35988567 |
[5] | World Health Organization. "International agency for research on cancer". (2019)[EB/OL]. https://www.iarc.who.int. |
[6] |
PARKIN D M, BRAY F, FERLAY J, et al. Estimating the world cancer burden: Globocan 2000[J]. Int J Cancer, 2001,94(2):153-156.
doi: 10.1002/ijc.1440 pmid: 11668491 |
[7] |
FERLAY J, SHIN H R, BRAY F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008[J]. Int J Cancer,2010,127(12):2893-2917.
doi: 10.1002/ijc.25516 pmid: 21351269 |
[8] | FERLAY J, SOERJOMATARAM I, DIKSHIT R, et al. Cancer incidence and mortality worldwide: sources, met-hods and major patterns in GLOBOCAN 2012[J]. Int J Cancer,2015,136(5):E359-E386. |
[9] | BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68(6):394-424. |
[10] | SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2021,71(3):209-249. |
[11] | BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2024,74(3):229-263. |
[12] |
FERLAY J, COLOMBET M, SOERJOMATARAM I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods[J]. Int J Cancer, 2019,144(8):1941-1953.
doi: 10.1002/ijc.31937 pmid: 30350310 |
[13] | United Nations Development Programme. Human deve-lopment report 2021-2022. uncertainTimes, unsettled lives: shaping our futurein a transforming world[R/OL]. United Nations,2022. https://hdr.undp.org/content/human-development-report-2021-22. |
[14] |
PARKIN D M. The evolution of the population-based cancer registry[J]. Nat Rev Cancer,2006,6(8):603-612.
doi: 10.1038/nrc1948 pmid: 16862191 |
[15] | VAN TONG H, BRINDLEY P J, MEYER C G, et al. Parasite infection, carcinogenesis and human malignancy[J]. E Bio Medicine,2017,15:12-23. |
[16] |
DE MARTEL C, FERLAY J, FRANCESCHI S, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis[J]. Lancet Oncol, 2012,13(6):607-615.
doi: 10.1016/S1470-2045(12)70137-7 pmid: 22575588 |
[17] | SCHMID V J, HELD L. Bayesian age-period-cohort mode-ling and prediction-BAMP[J]. J Stat Soft,2007,21(8):1-15. |
[1] | WANG Kangning, ZHU Lan, FENG Weiming, XIA Yihan, SHI Bowen, ZHANG Huan. Value of synthetic MRI in predicting treatment response to neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer [J]. Journal of Diagnostics Concepts & Practice, 2025, 24(02): 170-177. |
[2] | LUO Haijun, LIAN Yixiang, WANG Zhigan, JIANG Shali. Application of GYPC gene methylation detection in cervical cancer screening for HR-HPV-positive women [J]. Journal of Diagnostics Concepts & Practice, 2025, 24(01): 65-71. |
[3] | LEICHAO Wenwei, RAO Jialing, ZHOU Mengxue, YANG Hong. Advances in research on risk factors and associated diseases of intrapancreatic fat deposition [J]. Journal of Diagnostics Concepts & Practice, 2025, 24(01): 72-79. |
[4] | XU Mengdi, GAO Feng, ZHU Jian, CHEN Lei, QIN Yumeng, HUANG Yue, TANG Yinping, SHA Jie. Value of novel sponge capsules combined with AI-based cell DNA detection in early esophageal cancer screening [J]. Journal of Diagnostics Concepts & Practice, 2024, 23(06): 580-586. |
[5] | RUAN Miao, DA Qian, XU Haimin, DONG Lei, FEI Xiaochun. Study on clinicopathological features and prognosis of HER2 low expression breast cancer [J]. Journal of Diagnostics Concepts & Practice, 2024, 23(05): 500-508. |
[6] | FAN Bonan, LI Yan. Trends in global major disease burden and health conditions—interpretation of the Global Burden of Disease Study 1990-2021 [J]. Journal of Diagnostics Concepts & Practice, 2024, 23(05): 474-483. |
[7] | ZHANG Zhiping, CAI Shilong, GENG Yanlong, LIU Shiyou. Analysis of incidence trend of thyroid cancer in Baoshan District, Shanghai from 2000 to 2022 [J]. Journal of Diagnostics Concepts & Practice, 2024, 23(04): 378-384. |
[8] | FU Xina, XU Xin, LI Tianjie, JIN Ying. Study on the risk factors for persistent infection of high-risk human papillomavirus after cervical conization [J]. Journal of Diagnostics Concepts & Practice, 2024, 23(04): 416-423. |
[9] | ZHANG Xin, ZHENG Ying. Interpretation of cancer death burden data from disease surveillance sites in China from 2005 to 2020 [J]. Journal of Diagnostics Concepts & Practice, 2024, 23(04): 371-377. |
[10] | ZHANG Dongyan, LI Yan. Summary and interpretation of the World Health Organization “Global Report on Hypertension” [J]. Journal of Diagnostics Concepts & Practice, 2024, 23(03): 297-304. |
[11] | LIU Juan, YIN Lijuan, FAN Desheng. The clinicopathologic significance of AR, SKP2, SOX10, PD-L1 and TILs expression in triple-negative breast cancer [J]. Journal of Diagnostics Concepts & Practice, 2024, 23(02): 162-172. |
[12] | OU Dan, CAI Gang, CHEN Jiayi. Bioinformatics analysis for expression of RAD51AP1 in triple negative breast cancer with brain metastasis [J]. Journal of Diagnostics Concepts & Practice, 2024, 23(02): 146-154. |
[13] | DING Jingfeng, AO Weiqun, ZHU Zhen, SUN Jing, XU Lianggen, ZHENG Shibao, YU Jingjing, HU Jinwen. The value of radiomics based on T2WI and DWI of MRI in preoperative prediction of extramural vascular invasion in rectal cancer [J]. Journal of Diagnostics Concepts & Practice, 2024, 23(01): 46-56. |
[14] | ZHANG Ying, JIANG Xiaofei. Analysis of global burden of bacterial infections: an interpretation of Global mortality associated with 33 bacterial pathogens in 2019 [J]. Journal of Diagnostics Concepts & Practice, 2023, 22(06): 541-549. |
[15] | ZHAN Dui, NIMA Zhuoma, DOU Ji, PINGCUO Zhuoma, QI Jinlei. Analysis of all-cause mortality data of residents in Shannan City, Tibet, 2021 [J]. Journal of Diagnostics Concepts & Practice, 2023, 22(06): 562-566. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||